Artificial intelligence

FDA plans to fully tap real-world data and evidence

reprint The Food and Drug Administration plans to exploit claims, clinical and patient-generated data— information not captured through traditional clinical trials—for post-marketing safety surveillance. “New streams of real-world data gathered from electronic health records, lab tests, wearable devices, insurance claims and even social media can provide important evidence on product Czytaj więcej…